Thyroid. 2021 Oct 29. doi: 10.1089/thy.2021.0299. Online ahead of print.
ABSTRACT
Background The syndrome of thyrotoxicosis typically relies on radioactive iodine scans for establishing its etiology. Alternatively, the determination of TSH receptor antibodies (TRAb) helps to distinguish Graves' disease (GD) from thyrotoxic thyroiditis. Current assays are impacted by limitations in sensitivity and/or turnaround time. Therefore, we decided to test a new assay for the detection of TSH receptor stimulating antibodies (TSAb) and compare it with the clinically available assays. Methods We enrolled 110 individuals in 5 cohorts: patients with incident or recurrent Graves' disease (cohort 1); patients with thyroiditis, painless or subacute (cohort 2); patients with Graves' Orbitopathy/Thyroid Eye Disease (TED) in cohort 3; patients with Hashimoto's thyroiditis (cohort 4) and a control group of normal volunteers (cohort 5). The patients were tested with the two clinically available assays: Roche Elecsys anti-TSHR assay (ROC-TBII) from Roche Diagnostics and Thyretain™ TSI Reporter BioAssay Kit (QUI-TSI) from Quidel. In addition, the samples were tested with the aequorin TSAb assay (OTS-TSI) provided by Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). The data was collected in a cross-sectional fashion before initiation of therapy. Results We had 36 cases of GD, 17 cases of thyroiditis, 27 cases of TED, 10 cases of Hashimoto's thyroiditis and 20 normal volunteers. OTS-T SI had 100% sensitivity and specificity in distinguishing GD from thyroiditis, identical with QUI-TSI but superior to ROC-TBII (sensitivity 86% and specificity 94.1%). OTS-TSI had 93% sensitivity and 100% specificity for the diagnosis of TED, compared with normal controls. QUI-TSI and ROC-TBII performed similarly in this analysis, demonstrating 82% sensitivity and 100% specificity. The range of detectable values for OTS-TSI was 20 - 29,000 mIU/L and the turnaround time was ≤ 6 hours, without the need for cell culture equipment. Conclusions. OTS-TSI performed excellently, though similarly to QUI-TSI, for the differential diagnosis of GD versus thyroiditis, while being superior in that respect to ROC-TBII. Furthermore, OTS-TSI has superior sensitivity to QUI-TSI and ROC-TBII for TED diagnosis, while retaining high specificity. It has a short turnaround time and avoids the need for cell culture and sterility. Larger studies in US populations are needed for its validation.
PMID: 34714163 | DOI:10.1089/thy.2021.0299
No comments:
Post a Comment